NEWS IN PEDIATRIC GASTROENTEROLOGY PHARMACOLOGY
Recent advances of biological treatment in eosinophilic gastrointestinal disorders
Danilo Rossetti, Salvatore Oliva
U.O.C. di Gastroenterologia ed Epatologia pediatrica Dipartimento Materno-Infantile – AOU Policlinico Umberto I, Sapienza Università di Roma
Biological treatments could represent a valid alternative for treatment of eosinophilic gastrointestinal disorders) EGIDs. The most promising are monoclonal antibodies targeting IL-13 and IL4 which are currently being evaluated in phase 3 trials. Another potential therapy might include selective enzymatic inhibitors (small molecules). Here, we review the most significant studies and potential targets in the next future of eosinophilic gut disorders